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22.5 ml of blood fills the left atrium from the pulmonary vein
during systole. Because the systolic fraction of the pulmonary vein
is 56% (of the systo-diastolic flow), we can assume that the total
flow coming from the pulmonary vein (which reflects the total
forward stroke volume) is 40 ml. Consequently, for the reported
heart rate and body surface area, the cardiac index is 1.5 l/min/m2,
which is surprisingly low for a normal patient population. This
rough calculation is enforced by the observation during trans-
esophageal echocardiography that the diameter of the pulmonary
vein does not change so much during the entire cardiac cycle. It has
been shown that left atrial volume measured by echocardiography
is underestimated compared with both cine-computed tomography
(2) and magnetic resonance imaging (3). Would it not be useful to
consider a physiologic variable such as cardiac output to evaluate
the accuracy of volume measurement?
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REPLY
We appreciate the comments that Dr. Rossi expressed concerning
our recent study (1) “Compensatory Changes in Atrial Volumes
With Normal Aging: Is Atrial Enlargement Inevitable?” We are
grateful to be given the chance to respond to the issues raised in the
letter.
Our findings demonstrated that, in the younger age group, total
left atrial volume change (passive emptying volume  conduit
volume  active emptying volume) was approximately 60 ml per
cardiac cycle. Thus, one may extrapolate that the left ventricular
stroke volume in the absence of valvular regurgitation is approxi-
mately 60 ml. For a mean heart rate of 71 beats/min and body
surface area (BSA) of 1.8 m2, the cardiac output would be 4.3
l/min or 2.4 l/min/m2, which is a reasonable estimate for the
cardiac output of a normal young patient at rest. We agree with
Dr. Rossi that correlating the left atrial volume estimation with
cardiac output may be useful. However, we elected not to include
the data, as insertion of a pulmonary artery catheter for measure-
ment of cardiac output by thermodilution in our normal volunteers
was difficult to justify. Estimating stroke volume by measuring the
time velocity integral of the left ventricular outflow tract was not
included because the main thrust of the present study was on left
atrial volume.
Furthermore, we believe that estimation of total left atrial
volume change from pulmonary venous flow, which is suggested by
Dr. Rossi, would ignore the all-important contribution of active
atrial contraction to left ventricular filling, which would lead to an
underestimation. However, we would like to emphasize that the
potential for volume underestimation is always present with
echocardiography. Thus, when estimating atrial volumes echocar-
diographically, the atrial volume should be maximized by selecting
the largest frame, including the curve of the interatrial septum.
Moreover, we would also like to mention that the biplane atrial
volumes obtained from transthoracic images do not account for
atrial appendage blood volume. This exclusion of left atrial
appendage volume may cause the underestimation in total atrial
volume. Finally, when imaging at increased depths, the use of a
lower frequency transducer may provide greater penetration,
thereby optimizing atrial border visualization.
We sincerely hope that the above will adequately address the
concern raised in Dr. Rossi’s communication.
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Coronary Artery Bypass Graft Surgery
in Patients With Recent Exposure
to Clopidogrel and Aspirin Therapy
We read with great interest the study by Hongo et al. (1) entitled
“The Effect of Clopidogrel in Combination With Aspirin When
Given Before Coronary Artery Bypass Grafting.” This very inter-
esting study highlights an emerging problem for patients having
routine coronary artery bypass graft surgery (CABG) after percu-
taneous intervention, as described in their report, but also for
patients with an acute coronary syndrome who require urgent
“in-house surgery” because these patients are invariably on both
clopidogrel and aspirin therapy.
In their study, the investigators showed that continued clopi-
dogrel therapy within seven days of elective CABG results in
increased blood loss, increased use of blood products, and increased
re-exploration rates. Unfortunately, although the study was pro-
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spective there was no blinding of the nurses or clinicians to
clopidogrel and aspirin exposure.
This lack of blinding is crucial to determine whether the main
outcomes of the study are credible. The investigators acknowl-
edged that recording of blood loss may be biased, but so could the
decision to use blood and blood products (guidelines for the use of
blood and blood products were not stated in their report). Also, no
data were provided on the use of antifibrinolytic drugs. Use of
drugs like aprotinin and tranexamic acid in patients with a high
risk of bleeding is now well established, and this data would be
relevant, particularly in patients who underwent re-exploration
(2–4). Moreover, although the Society of Thoracic Surgeons’
guidelines for re-exploration were used, these are open to inter-
pretation, and the decision of a surgeon not blinded to clopidogrel
therapy may be biased.
In addition, there was no measure of platelet function to
demonstrate the fact that platelet aggregation was different be-
tween the two groups preoperatively and that this difference
persists postoperatively and therefore directly accounts for the
difference in postoperative bleeding and other outcome measures
used. This is particularly important because the time from last
clopidogrel dose to surgery ranged from 0 to 7 days, and in some
patients, particularly those in whom clopidogrel therapy was
stopped at least 5 days before surgery, other factors may have
caused bleeding. In the Clopidogrel in Unstable Angina to prevent
Recurrent Ischaemic Events (CURE) trial, patients in whom
clopidogrel therapy was halted less than five days before surgery
had a trend toward more major bleeding than those on placebo
(9.6% vs. 6.3%, p  0.06), whereas this trend was not seen in
patients in whom surgery was performed more than five days after
clopidogrel therapy was stopped (5).
In our experience, patients on clopidogrel and aspirin up to the
time of surgery can be operated on safely provided a pro-coagulant
drug like aprotinin or tranexamic acid is used intraoperatively. As
discussed by Hongo et al. (1), antiplatelet therapy that is continued
up to the time of surgery may be beneficial; in the case of aspirin
it may improve mortality (6), and clopidogrel may reduce platelet
activation owing to cardiopulmonary bypass (7,8). Until the
question of the role of a pro-coagulant and platelet-protective drug
(9) like aprotinin is defined, it is premature to conclude that
surgery for patients with a history of clopidogrel exposure within
seven days of operation should be delayed.
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REPLY
We are pleased that Dr. Akowuah and colleagues found our study
(1) of interest. We acknowledge the inherent limitations of the
study design, and we reiterate that further studies are needed to
better define the role of clopidogrel before coronary artery bypass
grafting (CABG) surgery. We believe it premature, however, to
dismiss the credibility of the main outcomes of this study based on
the lack of blinding. Chest tube output, the main measure of
postoperative bleeding, is a highly objective and straightforward
measurement. Because the nurses who recorded the amount of
drainage were not aware of the questions being evaluated by the
study, we have no reason to believe there was motive for misrep-
resentation. Reoperation for bleeding, the main clinical outcome,
although a more subjective end point, was directed by institutional
clinical guidelines. Patients went for reoperation when chest tube
outputs either exceeded 300 ml over 2 consecutive h, or 500 ml
over 1 h. As seen in Figure 1 of our study (1), patients with
clopidogrel exposure who underwent reoperation all had 24-h
chest tube outputs in excess of 4,000 ml, notably more than that of
other patients.
The concern raised by Dr. Akowuah and colleagues regarding
the use of antifibrinolytic agents is an important one. In our study,
aprotinin was administered to eight patients (13.6%) exposed to
clopidogrel and one patient (0.6%) without exposure. Any hemo-
static effect of this agent would be expected to reduce adverse
bleeding outcomes in the clopidogrel group, thus diminishing the
differences seen between the groups. Ever since the completion of
our study, we have started to use aprotinin routinely when
immediate surgery is unavoidable in patients with clopidogrel
exposure, and we are finding that perioperative bleeding is sub-
stantially reduced in most, but not all, cases. We echo the
sentiment that the role of preoperative antiplatelet therapy in
combination with antifibrinolytic agents is promising, but it is
a role that is still undefined. Until further studies establish the
efficacy of aggressive preoperative antiplatelet therapy, we
maintain that caution should be exercised when patients ex-
1422 Letters to the Editor JACC Vol. 41, No. 8, 2003
April 16, 2003:1420–3
